bca101,pembrolizumab,pds0101
bicara,hookipa pharmaceuticals,pds biotech,merck
['pds0101', 'bca101', 'keytruda', '$hook', 'bicara', '$pdsb']
orr in hpv+ h&amp;n cancer patients on 1l combination with keytruda, per #asco23 posters: $hook hb-200: 43% orr (6/14 patients with confirmed responses); $pdsb pds0101: 27% (9/33 patients with confirmed responses); bicara's bca101: 18%, i.e. ~ same as 19% orr for keytruda 1l alone 
Engineering background. 25+ yrs in the stock market. Early retired to trade full-time. Value-driven & CANSLIM. Inspired by Mark Minervini et al. Posts ≠ Advice.